WntResearch 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   23 News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Foxy-5 / WntResearch
2018-003074-27: Study in patients with colon cancer to evaluate the safety and tolerability of Foxy-5 treatment. Estudio en pacientes con cáncer de colón para evaluar la seguridad y tolerabilidad del tratamiento Foxy-5.

Not yet recruiting
2
180
Europe
Foxy-5, Lyophilisate for solution for infusion
WntResearch, WntResearch
Subjects with resectable adenocarcinoma of the colon and who, at the time of screening, are considered to fulfil the local criteria for adjuvant post-operative chemotherapy. Based on CT/MRI subjects should be judged to be: T1-4, N1-2, M0 or T4, N0, M0. La prueba se efectuará en sujetos con adenocarcinoma resecable del colon y que , en el momento de la selección, cumplan los requisitos locales para recibir quimioterapia adyuvante posoperatoria. Basado en CT/MRI, los sujetos deben considerarse T1-4, N1-2, M0 o T4, N0, M0, Colon cancer Cáncer de colon, Diseases [C] - Cancer [C04]
 
 
NeoFox, NCT03883802 / 2018-003074-27: Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer

Active, not recruiting
2
100
Europe
Foxy-5, FOLFOX regimen, Tumour resection (colon cancer surgery)
WntResearch AB, SMS-Oncology BV, SAGA diagnostics AB, Unilabs A/S, BioVica AB, Institut Català d'Oncologia
Colon Cancer
12/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Foxy-5 / WntResearch
2018-003074-27: Study in patients with colon cancer to evaluate the safety and tolerability of Foxy-5 treatment. Estudio en pacientes con cáncer de colón para evaluar la seguridad y tolerabilidad del tratamiento Foxy-5.

Not yet recruiting
2
180
Europe
Foxy-5, Lyophilisate for solution for infusion
WntResearch, WntResearch
Subjects with resectable adenocarcinoma of the colon and who, at the time of screening, are considered to fulfil the local criteria for adjuvant post-operative chemotherapy. Based on CT/MRI subjects should be judged to be: T1-4, N1-2, M0 or T4, N0, M0. La prueba se efectuará en sujetos con adenocarcinoma resecable del colon y que , en el momento de la selección, cumplan los requisitos locales para recibir quimioterapia adyuvante posoperatoria. Basado en CT/MRI, los sujetos deben considerarse T1-4, N1-2, M0 o T4, N0, M0, Colon cancer Cáncer de colon, Diseases [C] - Cancer [C04]
 
 
NeoFox, NCT03883802 / 2018-003074-27: Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer

Active, not recruiting
2
100
Europe
Foxy-5, FOLFOX regimen, Tumour resection (colon cancer surgery)
WntResearch AB, SMS-Oncology BV, SAGA diagnostics AB, Unilabs A/S, BioVica AB, Institut Català d'Oncologia
Colon Cancer
12/24
12/24

Download Options